Composition: Pregabalin 75 mg + Duloxetine 20 mg
PGTrion-D 75/20 is a combination therapy from DrugsWell, formulated for patients whose nerve pain needs more than a single-pathway approach. Neuropathic pain is often difficult for patients to explain because it may not look visible from the outside, yet it can strongly affect daily comfort, sleep, walking, work, and overall quality of life.
Patients may describe nerve pain as burning in the feet, tingling in the hands or legs, pins-and-needles sensation, sharp shooting pain, electric-current-like pain, numbness, or pain that keeps returning without a fresh injury. In such cases, the doctor may prefer a combination approach to support better nerve pain control.
PGTrion-D brings together Pregabalin 75 mg and Duloxetine 20 mg. Pregabalin is commonly used in nerve pain management, while Duloxetine adds value where pain sensitivity and discomfort need broader clinical support. Together, the combination gives doctors a practical option for structured neuropathic pain therapy, especially when symptoms are persistent or affecting the patient’s daily life.
For doctors, PGTrion-D 75/20 offers a focused combination that can be considered where patient symptoms suggest nerve involvement and treatment needs to be planned according to response, tolerability, age, associated conditions, and ongoing medicines.
For patients, PGTrion-D should be understood as a prescription medicine for nerve-related pain, not a routine painkiller for every body ache. It should be taken only under medical supervision, exactly as advised by the doctor. The dose, timing, and duration should not be changed without consultation.
Patients should inform their doctor if they experience excessive sleepiness, dizziness, nausea, dry mouth, swelling, unusual tiredness, mood changes, or any discomfort after starting the medicine. PGTrion-D should not be stopped suddenly unless advised by the doctor, because nerve pain treatment often needs regular follow-up and careful adjustment.






Reviews
There are no reviews yet.